Intellectual Property

Premier Biomedical has obtained exclusive world-wide license to the patents listed below.

Sequential Extracorporeal Treatment of Bodily Fluids

U.S. Patent No. 9,216,386

Issued December 22, 2015


An article and method to treat extracorporeally a patient’s bodily fluid.  The bodily fluid can include blood, cerebral spinal fluid and lymph.  A first stage of the method includes applying a treatment,  The treatment can comprise dosing with a medication, thermal treatment, or irradiation.  The treatment can occur at levels that could otherwise compromise the patient’s health,  A second stage of the method substantially removes the treatment from the bodily fluid.  The bodily fluid can then be returned to the patient.  The article includes a treatment chamber that applies the treatment and a removal module for removing the treatment.  The method can be a continuous process such as, for example, a dialysis process.

View the full patent here.

Medication and Treatment for Disease

U.S. Patent No. 8,865,733

Issued October 21, 2014


A treatment is described for diseases with symptoms that can include fatigue, muscle aches and spasms, weakness, demylenation, and nerve pain.  Diseases can include fibromyalgia, depression, and auto-immune and immuno-suppressive diseases such as MS.  The treatment comprises about 1-10 mg naltrexone, at least about 20 µg vitamin B12, at least about 5 mg vitamin B6, at least about 2 mg co-enzyme Q, and preferably at least one ancillary medication selected from the group consisting of diazepam, cyclobenzaprine, clonazepam, alprazolam, 9-tetrahydrocannibinol, fumarate, caffeine and combinations thereof.  The treatment can be administered orally , and an decrease mental and physical symptoms such as, for example, fatigue, gait problems, visual dysfunction, and pain while improving cognitive skills.

View the full patent here.


Utilization of Stents for the Treatment of Blood Borne Carcinomas

U. S. Patent No. 8,758,287

Issued June 24, 2014


A filter and a method treat blood borne carcinomas by inducing apoptosis in carcinoma cells.  The filter includes comprises a stent having an interior wall defining a channel containing a packing material and at least one antineoplastic agent.  The method includes placing a patient’s blood in apposition of the antineoplastic agent by pumping the blood through the stent.  The blood remains in apposition to the antineoplastic agent for a sufficient time period to induce an apoptotic cascade.

View the full patent here.